1) Before open! 2) So the IER low value of $0.30 post recap, post consol assumes annual: Revenue: $205m assumed vs $192.6m actual (1H 18 result annualised, -6% short) EBITDA: $28.7m assumed vs -$21.2m - a loss and for only 1H As EBITDA is still negative you can't even generate a positive EV based on the valuation methodology employed by KPMG. E.g. 4.75 x -21.2 = -$101m. Low: $0 High: $0.30 is still generous.
PTX This rare type of lymphoma ruins the body – so do existing treatments. Prescient could have a solution
(20min delay)